Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(100.0%)
2Total
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03198975Unknown

Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma

Role: lead

NCT03110068Unknown

Preoperative Estimation of Microvascular Invasion in Hepatocellular Carcinoma

Role: lead

NCT02645643Phase 3Unknown

Medical Education Intervention for Medical Students

Role: lead

NCT02678013Phase 3Unknown

RFA+Highly-purified CTL vs. RFA Alone for Recurrent HCC

Role: lead

All 4 trials loaded